Amgen Inc.
Amgen Inc (AMGN) is a large-cap biotechnology company specialising in human therapeutics, particularly biologic medicines. With a market capitalisation around $162 billion, Amgen generates revenue from established products across oncology, nephrology, inflammation and cardiovascular care, while investing heavily in a diverse R&D pipeline of biologics and novel therapies. The company benefits from recurring revenue from long-tenured biologics, a history of steady free cash flow and a shareholder-friendly dividend policy, but faces typical sector risks: clinical trial setbacks, biosimilar competition, pricing pressure and regulatory scrutiny. Investors should watch product patent expiries, pipeline readouts and any M&A activity. This summary is for educational purposes only and not personalised investment advice; suitability depends on an investor’s goals, timeframe and risk tolerance, and returns are not guaranteed.
Why It's Moving
AMGN Stock Warning: Why Analysts See -11% Downside Risk
- Bernstein downgraded AMGN to Market Perform, citing Repatha's growth at risk from Merck's upcoming oral rival Enlicitide, which could intensify price wars in cholesterol treatments.
- Freedom Capital shifted to Hold as shares near fair value, even after raising revenue forecasts based on Amgen's strong low-end 2026 guidance that beat expectations.
- Barclays launched coverage with Equal Weight and a below-current-price target, noting ample time before Phase 3 MariTide results, tempering near-term upside from the obesity contender.
AMGN Stock Warning: Why Analysts See -11% Downside Risk
- Bernstein downgraded AMGN to Market Perform, citing Repatha's growth at risk from Merck's upcoming oral rival Enlicitide, which could intensify price wars in cholesterol treatments.
- Freedom Capital shifted to Hold as shares near fair value, even after raising revenue forecasts based on Amgen's strong low-end 2026 guidance that beat expectations.
- Barclays launched coverage with Equal Weight and a below-current-price target, noting ample time before Phase 3 MariTide results, tempering near-term upside from the obesity contender.
When is the next earnings date for Amgen Inc. (AMGN)?
Amgen's next earnings date is estimated for April 29-30, 2026, covering the Q1 2026 quarter, based on historical reporting patterns and analyst projections. This follows the most recent Q4 2025 report released on February 3, 2026. Official confirmation from the company is pending, with estimates varying slightly across sources.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Amgen's stock, believing it has good potential for price growth.
Financial Health
Amgen is performing well with strong revenue and cash flow, indicating healthy financial stability.
Dividend
Amgen's dividend yield of 2.6% offers a modest return for investors seeking dividends. If you invested $1000 you would be paid $26 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring AMGN
Hypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketNext-Gen Multiple Myeloma Treatments
Discover biotech companies at the forefront of revolutionary cancer treatments. These carefully selected stocks represent innovators developing cutting-edge immunotherapies for multiple myeloma, a common blood cancer with significant unmet medical needs.
Published: July 3, 2025
Explore BasketProfit Sharers
These established market leaders don't just generate impressive profits—they're committed to sharing that wealth with you. Carefully selected by our analysts, these dividend powerhouses offer both reliable income streams and the stability of industry-leading businesses.
Published: June 17, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Established Biologics Revenue
Amgen’s marketed biologics provide recurring sales and predictable cash flow, though revenue can be affected by patent loss and biosimilar entrants.
Pipeline & R&D Focus
A deep R&D pipeline drives long-term potential; positive trial results can re-rate the business, while failures can materially affect value.
Global Market Exposure
Amgen sells worldwide, benefiting from geographic diversification, but faces regional pricing and regulatory differences that can influence performance.
Compare Amgen with other stocks
Amgen vs Gilead Sciences
Amgen vs Gilead Sciences: Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
